Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the
safety and effectiveness of the VitaSmart Liver Machine Perfusion System by comparing
clinical outcomes in patients undergoing liver transplantation with ex-vivo liver
prese...
Age: 18 years - 66+
Gender: All
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and
Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Age: 18 years - 66+
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver
transplantation as an option, even if controversial. In sicker recipients, LT results in
immediate survival, but poor medium-term survival rates in some studies. The scarcit...
Age: 18 - 80 years
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of...
Age: 18 - 80 years
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression
of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an
accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing l...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
Longitudinal Study of Mitochondrial Hepatopathies
The specific aims of this study are (1) to determine the clinical phenotypes and natural
history of hepatic RC and FAO disorders, (2) to determine the correlation between genotype
and phenotype, (3) to determine if circulating biomarkers reflect diagnosis and predic...
Age: Birth - 18 years
Gender: All
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Cholestasis is a condition in which bile is not properly transported from the liver to the
small intestine. Cholestasis can be caused by an array of childhood diseases, including the
genetic diseases Alagille syndrome (ALGS), alpha-1 antitrypsin (a-1AT) deficiency, ...
Age: Birth - 25 years
Gender: All
DILIN's Prospective Study
The purpose of this study is to identify individuals who have suffered a liver injury arising
as an idiosyncratic reaction to a prescription drug or a complementary and alternative
medicine. Recently added acute cases enrollment that meets criteria to the protocol. ...
Age: 2 years - 66+
Gender: All
A Prospective Database of Infants With Cholestasis
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions
are the most common causes of jaundice and hyperbilirubinemia that continue beyond the
newborn period. The long term goal of the Childhood Liver Disease Research Network (Chi...
Age: Birth - 6 months
Gender: All